Nicoletta C Machin

Dr. Nicoletta C Machin

Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Journal of Blood Medicine
Verified
Journal Article
Open access
PDF file
Nicoletta C MachinNicoletta C Machin
Nicoletta C Machin
MRMargaret V Ragni
Margaret V Ragni
Fitusiran is an RNA interference therapeutic that targets antithrombin (AT) in the liver and interferes with AT translation by binding and degrading messenger RNA-AT, thereby silencing AT gene expression and preventing AT synthesis. In both preclinical and clinical studies, AT knockdown results in dose-dependent AT lowering when fitusiran is given weekly or monthly subcutaneously. In clinical trials, fitusiran dose escalation has resulted in improved thrombin generation and clinical hemostasis as measured by reduction in annualized bleed rate. Unlike currently licensed drugs, this improvement was not only in patients with hemophilia A but in also those with hemophilia B, with or without inhibitors. In dental and surgical procedures, fitusiran also provided perioperative hemostasis in association with AT lowering. Fitusiran is well tolerated, with minor local injection site reactions, but in one subject with severe hemophilia A, the concomitant use of daily high-dose factor VIII, inconsistent with trial guidance to avoid high, repeat doses of clotting factor, was associated with fatal thrombosis, suggesting the need for caution when using hemostatic agents in conjunction with fitusiran. Preclinical in vitro and in silico studies indicate improvement in thrombin generation in rare bleeding disorder plasmas, including in plasmas from patients with severe factors V, VII, and X deficiency, suggesting potential therapeutic benefit.

24 July 2018 in Blood Advances
Verified
Journal Article
Open access
PDF file
Nicoletta C MachinNicoletta C Machin
Nicoletta C Machin
MRMargaret V. Ragni
Margaret V. Ragni
KSKenneth J Smith
Kenneth J Smith
Key Points: Gene therapy is cost-effective in severe hemophilia A compared with standard factor VIII prophylaxis. Over a 10-year time horizon, gene therapy cost $1M and resulted in 8.33 QALYs gained, whereas prophylaxis cost $1.7M and resulted in 6.62 QALYs gained.

4 February 2016 in Haemophilia
Verified
Journal Article
Closed access
PDF file
MRM. V. Ragni
M. V. Ragni
Nicoletta C MachinNicoletta C Machin
Nicoletta C Machin
LML. M. Malec
L. M. Malec
AJA. H. James
A. H. James
CKC. M. Kessler
C. M. Kessler
DBD. J. Brambilla
D. J. Brambilla

1 December 2018 in Thrombosis Research
Verified
Journal Article
Closed access
Nicoletta C MachinNicoletta C Machin
Nicoletta C Machin
MRMargaret V. Ragni
Margaret V. Ragni
DCDiane M. Comer
Diane M. Comer
JYJonathan G. Yabes
Jonathan G. Yabes

1 November 2020 in Translational Research
Verified
Journal Article
Closed access
Nicoletta C MachinNicoletta C Machin
Nicoletta C Machin
MRMargaret V. Ragni
Margaret V. Ragni

21 July 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
Nicoletta C MachinNicoletta C Machin
Nicoletta C Machin
MRMargaret V. Ragni
Margaret V. Ragni
Von Willebrand disease (VWD) is a congenital bleeding disorder characterized by deficient or defective von Willebrand factor (VWF). Among women with VWD, postpartum hemorrhage (PPH) is common. Treatment options at delivery include plasma-derived VWF (pdVWF) and recombinant VWF (rVWF). However, limited data are available regarding their efficacy. We conducted a retrospective observational study comparing PPH in women with VWD treated at the Hemophilia Center of Western Pennsylvania between 1 February 2017 and 31 January 2018 with either rVWF or pdVWF. We compared postpartum outcomes, including PPH frequency and estimated blood loss (EBL) at delivery. There were a total of 12 deliveries, 7 vaginal and 5 cesarean. At delivery and for 3 days postpartum, 6 women received 80 IU/kg of rVWF and 6 received 80 IU/kg of pdVWF, based on prepregnancy weight, insurance, and/or patient choice. Treatment groups had similar demographics, including median age (32.0 vs 27.0 years; P = .075), bleeding scores (3.0 vs 3.5; P = .734), and prepregnancy body mass index (29.0 vs 29.2 kg/m2; P = .691). PPH occurred in 3 (25.0%) of 12 deliveries, with no difference by treatment group (2 of 6 rVWF vs 1 of 6 pdVWF; P = 1.000) and no difference in EBL by treatment group (685 vs 462 mL; P = .384) or delivery type (vaginal, P = .722 vs cesarean, P = .531). In summary, PPH occurred in one-fourth of the deliveries in women with VWD, despite a higher dose (80 IU/kg) of rVWF or pdVWF. Future trials are needed to develop and assess novel strategies to prevent PPH in VWD.